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ISCTE-IUL – Economics, Lisbon, PortugalA B S T R A C TBackground: Cost ﬂuctuations render the outcome of any treatment
switch uncertain, so that decision makers might have to wait for more
information before optimally switching treatments, especially when
the incremental cost per quality-adjusted life year (QALY) gained
cannot be fully recovered later on. Objective: To analyze the timing of
treatment switch under cost uncertainty. Methods: A dynamic sto-
chastic model for the optimal timing of a treatment switch is
developed and applied to a problem in medical decision taking, i.e.
to patients with unresectable gastrointestinal stromal tumour (GIST).
Results: The theoretical model suggests that cost uncertainty reduces
expected net beneﬁt. In addition, cost volatility discourages switching
treatments. The stochastic model also illustrates that as technologies
become less cost competitive, the cost uncertainty becomes more
dominant. With limited substitutability, higher quality of technologiessee front matter Copyright & 2014, International S
r Inc.
1016/j.jval.2013.12.008
scte.pt.
ndence to: Felipa de Mello-Sampayo, ISCTE-IUL, Ecwill increase the demand for those technologies disregarding the cost
uncertainty. The results of the empirical application suggest that the
ﬁrst-line treatment may be the better choice when considering life-
time welfare. Conclusions: Under uncertainty and irreversibility, low-
risk patients must begin the second-line treatment as soon as
possible, which is precisely when the second-line treatment is least
valuable. As the costs of reversing current treatment impacts fall, it
becomes more feasible to provide the option-preserving treatment to
these low-risk individuals later on.
Keywords: cost uncertainty, decision analysis, economic evaluation,
health economics, switch treatments.
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For some diseases, patients receive a sequence of treatments.
These may involve different drugs or different dosages of the
same drugs. The decision regarding whether to move a patient to
the next treatment in a sequence may be based on patient
characteristics or patient history, and therefore subject to varia-
bility. If it is accepted that adoption decisions should be made
with consideration of the associated decision uncertainty, then
we may say that models submitted to decision makers should do
two things: estimate expected net beneﬁt (NB) and characterize
decision uncertainty. If this dual purpose of models is accepted,
failure to fulﬁll the latter requirement will limit its value for
decision making and leave the decision maker without a key
element of information.
The decision to adopt a particular technology should be based
on the expected NB so that when comparing mutually exclusive
treatment strategies for a particular disease, the optimal strategy
is simply the one with the highest expected NB [1]. Nevertheless,
decisions based on the expected NB are appropriate only if there
is also some consideration of whether current evidence is sufﬁ-
cient for allocating health care resources, based on an assessment
of the consequences of decision uncertainty [2]. If the decisionuncertainty and the consequences of adopting a suboptimal
treatment strategy are large, the decision maker may require
further evidence on which to base the adoption decision [3].
For example, adopting some medical technologies restricts
the use of certain medical technologies in the future, and
explains the lack of consensus about when to start therapy in
HIV patients [4,5]. Some advocate ﬁghting HIV with a powerful
combination of drugs as early as possible in the course of the
disease to prevent the disease from progressing. Others are
concerned that starting therapy at early stages may lead to the
development of viral resistance to these drugs and related
compounds and the disease may progress to an advanced stage
more rapidly, while other clinicians advocate waiting until the
disease reaches a more advanced stage to initiate treatments so
that future options can be preserved. This problem of current
decisions affecting future options has received considerable
theoretical attention in the literature on economic investments.
The higher the uncertainty about future outcomes, the more
individuals will gain from waiting for more information before
committing to investment (or dis-investment) whenever there
are signiﬁcant sunk costs [6]. This result is a prediction of the
“option-pricing” approach to the analysis of irreversible invest-
ment under uncertainty [7–9]. Analogously, beneﬁts associatedociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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and beyond the direct value associated with those actions, are
referred to as the option value of the intervention [10].
For many physicians the observation that current medical
treatment decisions have repercussions for the treatment of
health conditions in the future is an obvious one that is often
considered in their clinical decision making. Such considerations
form no part of health care technology assessment calculations,
leading to potentially signiﬁcant mischaracterizations of the
treatment value. While it is difﬁcult to systematically assess the
size of the bias induced from ignoring option values, the only
empirical study in the health domain found an increase in
consumer willingness-to-pay of approximately 53% when option
values were considered [11].
Using the option-pricing approach for the analysis of irrever-
sible treatment choices under uncertainty is important because
the health sector is one in which there is tremendous uncertainty
about the demand for future medical technologies. When we begin
treating a population of individuals, we do not know what addi-
tional conditions they will develop in the future. Because new
diseases are constantly emerging, we do not even necessarily
know the nature of these future conditions. Higher life expectancy
prospects for new conditions to arise, especially those associated
with aging such as cancer and dementia, make the option value of
the interventions a key variable of the valuation equation. Ignoring
option values during the drug approval and reimbursement setting
process could result in disincentives to create socially valuable
technologies. Finally, unlike many private investment decisions,
decisions taken by national health systems may be effectively
irreversible for political reasons. Palmer and Smith [12] focus on
the timing of health investments and whether it makes sense to
delay the adoption of a new technology in anticipation of the
exogenous arrival of new information about its value. While the
prospects for delaying investments have potentially important
implications for decision making, delay is often not feasible in
this setting, especially on the time scale under which we expect
new information to arrive. When analyzing situations in which
current treatment decisions have irreversible implications for the
treatment of future diseases, and decision makers are choosing
between competing interventions with differing temporal conse-
quences, Zivin and Neideill [10] ﬁnd that irreversibility raises the
value of treatment modalities that preserve future treatment
options. Introducing some reversibility, however, can either
increase or decrease the option value, depending on the distribu-
tion of patient types. These authors also examine the relationship
between these values and the biological and economic parameters
that characterize any given set of technologies. Meyer and Rees
[13] analyze the treatment decision at a general level. They
determine optimal threshold values for initiating the intervention,
and derive comparative statics results with respect to model
parameters. In particular, an increase in the degree of uncertainty
over the patient’s health state, in most cases, makes waiting more
attractive. This may not hold, however, if the patient’s health state
has a tendency to improve.
This article follows the theory very closely to develop a
dynamic stochastic model for the optimal timing of a treatment
switch. Its main value addition consists in the concrete application
to a problem in medical decision taking, that is, to patients with
unresectable gastrointestinal stromal tumor (GIST). In the stochas-
tic model, we assume two lines of treatment in treating a chronic
disease and we consider the problem of a patient who is using the
ﬁrst-line treatment but the decision maker is contemplating
switching to a second-line treatment that consists of higher doses
of the drug used in the ﬁrst-line treatment and then provide a
more advanced drug. The patient will use the new line treatment
only if such a move is deemed beneﬁcial in the medium and long
term. That, in turn, will depend on the perceived evolution of cost.The higher the uncertainty regarding the cost of a new treatment,
the more likely it is that a favorable situation will turn into an
unfavorable one, and the more the patient will gain from waiting
for more information before committing to the new treatment
whenever the incremental cost per quality-adjusted life-year
(QALY) gained cannot be fully recovered later on.
With the aim of empirically testing this study’s option-pricing
model, an empirical application uses data from a modeling
exercise that compared alternative treatment pathways for
patients with unresectable GIST who failed to respond to imati-
nib 400 mg/d [14]. The study of Hislop et al. [14] assessed the
effectiveness and cost-effectiveness of imatinib at escalated
doses of 600 and 800 mg/d following progression of disease at a
dose of 400 mg/d, compared with sunitinib, or the provision of
best supportive care (BSC) only for patients with unresectable
and/or metastatic GISTs. Several studies have reported further
disease control after progression on an initial imatinib dose of
400 mg/d with dose escalation of imatinib to 800 mg/d, and this
has also become common practice [15,16]. However, it should be
noted that current National Institute for Health and Care Excel-
lence guidelines for imatinib do not actually recommend dose
escalation for patients with unresectable and/or metastatic GISTs
who progress on an initial dose of 400 mg/d [17] but suggest that
clinical decisions be made on an individual case-by-case basis,
reﬂecting uncertainty regarding optimal practice.
Three studies [18–20] compared imatinib with BSC. The study
by Wilson et al. [18] used the manufacturer submissions (Novartis
model) and compared imatinib and BSC, but in the imatinib
group allowed for escalation of doses from 400 to 600 mg/d for
those who failed to respond or were intolerant to imatinib at the
400 mg/d dose. The study by Mabasa et al. [20] noted that patients
included from retrospective cohorts in their analysis were given
imatinib 400 mg/d until disease progression, and later were
allowed escalated doses of between 600 and 800 mg/d. Six of 56
patients in the imatinib group of patients considered in this
economic evaluation were then allowed to switch to sunitinib
therapy. The economic evaluation by Huse et al. [19] considered
imatinib at 400 mg/d. Two studies [21,22] compared both imatinib
and sunitinib with BSC for patients who had failed or become
resistant to imatinib 400 mg/d.
The empirical application of this study assumes that patients
in the ﬁrst-line treatment are being treated with 400 mg/d and
the second-line treatment consists of dose escalation of imatinib
to 600 mg/d followed by sunitinib. Empirical results suggest that
the existence of an option value means that the ﬁrst-line treat-
ment may be the better choice when considering lifetime welfare.
Thus, under irreversibility, low-risk patients must begin the
second-line treatment as soon as possible, which is precisely
when the second-line treatment is least valuable. As the costs of
reversing current treatment impacts fall, it becomes more fea-
sible to provide the option-preserving treatment to these low-risk
individuals later on.
This article is organized as follows. The following section
develops the stochastic option-pricing model, specifying the two
feasible treatments and examining the effect of cost shocks on
both the timing of treatment switching and the NB of each
treatment. The next section presents the probability and
expected time of treatment switch. The discussion of the results
with an empirical application is presented in the following
section. Conclusions are discussed in the last section.The Model
In this section, we develop a model to illustrate the role that
uncertainty and irreversibility can play in determining the deci-
sion regarding whether to move a patient to the next treatment
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treating a chronic disease, denoted by L1 and L2, respectively.
The ﬁrst-line treatment consists of exclusively using one tech-
nology denoted by T1. The second-line treatment consists of
using a higher dosage of T1 and then starting with a different
technology, denoted by T2. We start constructing a one-sector
model that allows health capital to augment through public
investment. Then, we determine the NB of using Ti, i ¼ {1, 2}.
Finally, we deﬁne each line of treatment and show that when the
patient is using L1 the decision as to whether to use the second-
line treatment, L2, constitutes an optimal stopping problem.
Assume a one-sector model that allows health capital to
augment through public investment. In particular, an individual’s
health status is determined by public health measures such as
provision of clinical facilities, sanitation, inoculation, and disease
control programs (see Chakraborty [23]). Population individuals
are endowed with one unit of labor that is inelastically supplied
to ﬁrms, and receive wage income at the rate wt. Public health
expenditure in period t is ﬁnanced through a constant tax τ A (0,
1) on labor income so that health investment per person equals
τw. Such investment augments private health capital through a
constant returns technology:
ht ¼ τwt ð1Þ
Decision makers observe and decide the viability, utility, and
characteristics of health care goods and services only after using
those products or services. Thus, the quality of health care goods
or services can be ascertained only on their consumption. In such
cases, a drop in price is often interpreted by the prospective
consumer as a drop in quality or utility of the product or service.
Indeed, it is possible for the demand curve for medical care to be
upward sloping, even though medical care is a noninferior good,
a relationship that has some empirical support [24–26]. Housing
is another example of a noninferior good whose own demand can
be upward sloping (see Dusansky and Koç [27]). Under this
hypothesis, the demand for medical care is given by
Ti ¼ Bithφt ; ð2Þ
where Ti, i ¼ {1, 2} is the total quantity demanded of a health care
good or service at time t, Bit is the beneﬁt gain at time t, and φ is
the parameter for the elasticity of demand. We consider that
medical care operates where a patient’s demand for treatments is
inelastic, 1 o φ o 1. An example of a perfectly inelastic demand
would be a lifesaving drug that people will pay any price to
obtain. Even if the price of the drug were to increase dramatically,
the quantity demanded would remain the same. In this model
set-up, the mechanism that leads health to be a Giffen good also
involves a wealth consideration; when the price of treatment
falls, the patient is effectively wealthier, he or she can afford
more treatments generally, and so, he or she needs fewer treat-
ments of this kind. From Equation 2, the beneﬁt function of a
representative patient is given by
Bit ¼
Ti
hφt
: ð3Þ
The beneﬁt increases with the number of health care goods or
services demanded, but it is inversely related to the per capita
health investment. The higher a patient’s health capital, the
fewer health care goods or services he or she needs for the same
beneﬁt. The cost of the technology, Cit, i ¼ {1, 2}, is a nonlinear
function of a patient’s particular characteristic, x, that evolves
over time:
Cit ¼ rkx2t , ð4Þ
where r is the interest rate, k is the capital invested in the
technology, and x is the level of the state variable that represents
the random shock of the cost side at time t. For analyticaltractability, the state variable is assumed to evolve according to
a geometric Brownian motion:
dx¼ axdtþ sxdz ð5Þ
where dz¼ εt
ﬃﬃﬃﬃﬃ
dt
p
is the increment of a Wiener process and
εt↷Nð0,1Þ, Eðεt,εsÞ ¼ 0 f or sat
Equation 5 implies that the current value of the random shock is
known, but the future values are log-normally distributed with a
variance growing linearly with the time horizon.
The value of each technology is expressed in terms of NBs,
that is, the value of health beneﬁts generated by Ti, i ¼ {1, 2}, at
time t, ½ðBitÞ, minus the cost of that technology, ½ðcitÞ. The NB from
treatment with T1, at time t, is denoted by NB1t and the NB from
using T2 is denoted by NB2t. The NB for the patient using Ti, i ¼
{1, 2}, is as follows:
NBit ¼ BitCit ð6Þ
Under uncertainty, the decision to adopt a particular technology
is based on the expected present discounted value of the NB, so
that when comparing mutually exclusive treatment strategies for
a particular disease, the optimal strategy is simply the one with
the highest expected present discounted value.
Proposition 1: Higher volatility of a patient’s particular characteristic
reduces the expected NB associated with both technologies.
Proof: See Appendix A in Supplemental Materials found at http://
dx.doi.org/10.1016/j.jval.2013.12.008.
Comparing the state variables in Equations 17 and 18 in
Appendix A, the expected NB is proportional to
xδ, δ¼ 2ðφ1Þ=φ,
under both technologies. Recalling that medical care operates
where the patient’s demand for health care good or service is
inelastic (φ o 1), it follows that δ o 0. Consequently, cost
uncertainty reduces the expected NB under both technologies.
Under our model set-up, the magnitude of this adverse effect is
identical for both technologies.
Two Lines of Treatment
We assume two lines of treatment in treating a chronic disease.
The ﬁrst-line treatment, L1, consists of exclusively using T1 and
the second-line treatment, L2, consists of using a higher dosage of
T1 and then starting with T2. When the patient is exclusively
using T1, the decision as to whether to use the second-line
treatment constitutes an optimal stopping problem for which
the relevant Bellman equation is as follows:
V1ðx,tÞ ¼ Max V2;NB1 þ lim
dt-0
1
dt
Ex dv
1
h i 
ð7Þ
where V1(x, t) is the option value of intervention associated
with using the second-line treatment, V2 accounts for the
expected value gain that results from switching treatment and
starting the second-line treatment, and the second term in curly
brackets yields the time-discounted expected increment in the
value of the option that arises from keeping the option unexer-
cised for an additional lapse of time, dt. The range of values for
which the second term in curly brackets, in Equation 7, is greater
than the ﬁrst deﬁnes the continuation region, in which it is
optimal not to exercise the option.
During the second-line treatment, patients are offered a
higher dosage of T1 for the ﬁrst t periods, after which point they
switch to T2. Letting t be the parameter for the time at which T2
will be used during the second-line treatment, the value of the
optimal treatment switch, V2ð ~xÞ, is given by the NB after using T2
minus the incremental cost per quality-adjusted life-year (ICQALY)
gain of using a higher dosage of T1, that is, the value of QALY
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V2 ¼ Ex
Z 1
~t
NB2teμð1tÞdt
 

Z ~t
0
ICQALYeμð1tÞdt ð8Þ
where ~t denotes the time at which T2 will be used, and ICQALY
stands for the incremental cost of quality-adjusted life-year
(QALY) gain of using a higher dosage of T1. QALY measures the
cost of disease burden, including both the quality and the
quantity of life lived. ICQALY measures the QALY value wasted
when using a higher dosage of T1 instead of using the more
advanced technology T2. The ﬁrst term in Equation 8 reﬂects the
expected returns under T2, and the second term reﬂects the
expected penalty associated with the higher dosage of T1.
Proposition 2: Treatment switch occurs only if the relative
beneﬁt associated with T2 exceeds the present value of the relative
cost of T2.
Proof: See Appendix A in Supplemental Materials found at http://
dx.doi.org/10.1016/j.jval.2013.12.008.
In Equation 26 in Appendix A, ~x is the critical value, that is,
the value above and beyond the direct value of the second-line
treatment. When ~x > 0, the value associated with using the
second-line treatment exceeds that of a situation of using the
ﬁrst-line treatment. It follows from Equation 26 and the assump-
tions on the parameters that the value of x is greater than 0 if
ϕ
1φ
φ eμðtÞ
 
4π
1
φ,
implying that the decision maker will switch to second-line
treatment only if the relative beneﬁt associated with T2 exceeds
the present value of the relative cost of T2 weighted geometrically
by the elasticity of demand, and that is due to the uncertainty of
treatment’s cost.
Moreover, because
∂ ~x
∂s2
4 0 and lims-1 ~x ¼1,
the greater the volatility of the cost (i.e., the higher s2), the higher
the critical value has to be to make it optimal for the decision
maker to switch to the second-line treatment. The higher the
expected trend of the treatment’s cost, the less the option of
using the second-line treatment is worth, and thus the lower the
value that triggers the use of T2, that is,
∂ ~x
∂α
o 0,
The reason for this is that the more expensive one expects
technology to become, the lower the uncertainty that results
from the switch from a situation of using the ﬁrst-line treatment
to one in which the patient uses the second-line treatment.
With regard to the discount rate, the greater the agent’s time
discount rate, the less he or she values the option, and thus the
lower the value x that triggers optimal treatment switch; that is,
∂ ~x
∂μ
o 0
This result stems from the fact that a higher time preference
increases the decision maker’s opportunity cost of not immedi-
ately using the second-line treatment. In the extreme case in
which the decision maker cares only about the present moment,
so that μ - 1, then
limμ-1
β1
β1φ
¼ 0 and ~x ¼ 0,
so that uncertainty is disregarded and the value of the second-
line treatment option collapses to 0.
The greater the tax rate, the higher the patient’s health
capital; thus, the more decision makers value using the second-line treatment option, and thus the higher the value ~xthat
triggers optimal T2 use; that is,
∂ ~x
∂τ
4 0:
Last, the lower the relative cost of T2, the higher the relative
beneﬁt of T2 and the sooner T2 will be used, the lower the
threshold for using the second-line treatment.
∂ ~x
∂π
o0, ∂ ~x
∂ϕ
40 and
∂ ~x
∂~t
o0:The Timing and Probability of Switching to Second-
line Treatment
Before proceeding to the empirical application, it would be
interesting to ascertain, from any point within the continuation
region, the likelihood that using the second-line treatment will
become optimal in the future. It is important for the decision
maker to know the expected time that will transpire until the
decision of using the second-line treatment becomes optimal.
Using standard properties of the Brownian motion and the
lognormal distribution (see Dixit [28] and Øksendal [29]), closed-
form solutions for the probability Q(x) and the expected time T(x)
for the process x to hit the barrier ~x from any point inside the
continuation region are given by
QðxÞ ¼
1 if αr 12 s2
e
ð2αs2Þ lnð ~x=xÞ
α2
h i
if α4 12s
2
8><
>: ð9Þ
TðxÞ ¼
1 if αZ 12 s2
lnð ~x=xÞ
α12s2
if αo 12 s2
8<
: ð10Þ
where α – (s2/2) and s2 are, respectively, the drift and variance
parameters of the process x.
Equations 9 and 10 indicate that the probability and expected
time until using the second-line treatment to become optimal
depend on the variability and trend of the patient’s particular
characteristic. The greater is the variability, s2, the higher is the
likelihood that x diverges away from the threshold that triggers
the use of the second-line treatment, and so the lower the
probability that using the second-line treatment will ever become
optimal. Similarly, the higher the drift, α, the more likely long
excursions of x away from the critical ratio become, and so, the
more time the system is expected to take until hitting the
threshold beyond which using the second-line treatment is
optimal.
Using the second-line treatment will become optimal with
certainty provided that α o (s2/2), and it is expected to occur
sooner the higher x and the lower s2. For the limiting case in
which α ¼ (s2/2), even though the probability that the patient will
start using the second-line treatment in the future is 1, the
expected time for it to occur is inﬁnite. The intuition behind this
apparently contradictory result is that if the drift of x is 0, long
diversions away from the barrier ~x might occur. Thus, because
the probabilities for successfully longer hitting times do not fall
sufﬁciently fast, the expectation, which is the average of the
possible hitting times weighted by their respective probabilities,
diverges. This argument is presented in Dixit [28].
For the set of parameters for which x has a positive drift, that
is, when α > (s2/2), there is still a positive probability that using
the second-line treatment will become optimal sometime in the
future, as given by Equation 9. This is because in spite of x drifting
away from the critical ratio, there is the possibility that a
combination of positive shocks might just bring the system
toward the threshold barrier. The expected time for this event
Fig. 1 – Critical value for cost uncertainty and trend values.
Fig. 3 – Critical value for cost-quality relationship.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 2 1 5 – 2 2 2 219is inﬁnite, however, as given by Equation 10, given that there is a
positive probability that x never reaches ~x that drives the expect-
ation into diverging.Empirical Application
The model presented gives clear indications regarding treatment
switch decisions under cost uncertainty. It predicts that the
higher the volatility of the patient’s particular characteristic,
the sooner T2 is used, the higher the tax rate and the higher
the relative cost of T2, the more valuable the option of using the
second-line treatment will be, and so the fewer switches of
treatment will be observed. Conversely, the higher the trend of
the patient’s particular characteristics, the higher the discount
factor and the higher the relative beneﬁt of T2, the more switches
of treatment one would expect to observe. Thus, for empirical
testing purposes, the reduced form of Equation 12 can be written
as follows:
treatment switch¼ f s
2 α μ ~t τ π ϕ
 þ þ   þ 
 !Fig. 2 – Critical value for cost uncertainty and discount rate
values.These results are extended for Equation 26 in Appendix A by
using simulations. The simulations are performed against a
benchmark case. The data in the present application consist of
the cost-effectiveness of imatinib for GISTs [18]. The data are
described in detail in Appendix B. Current guidelines at the time
of the assessment recommended an initial dose of 400 mg/d, with
the option of proceeding to a higher dose in the event of a poor
response or disease progression, and withdrawal of treatment in
the absence of beneﬁt after 8 weeks. Nevertheless, because of a
paucity of data, the best starting dose of imatinib and best
treatment pattern were highly uncertain. The model had four
health states: progressive disease, treatment with 400 mg imati-
nib, treatment with 600 mg imatinib, and death. Patients in the
imatinib treatment group began with 400 mg/d. For those
patients who failed to respond to 400 mg imatinib, a random
number was generated to determine whether they would be
moved to 600 mg, or straight to the progressive disease state.
The probability of receiving 600 mg was based on the number of
patients who had responded after crossing over from 400 to 600
mg imatinib in a clinical trial. We assume that patients start with
400 mg/d and the second-line treatment consists of dose escala-
tion of imatinib to 600 mg/d followed by sunitinib.
Figures 1 to 5 provide a sensitivity analysis of the trigger value
~x with respect to the following parameters of the model:
s, α, μ, ~t, τ, π, and φ. The parameters are calibrated with valuesFig. 4 – Critical value for cost uncertainty and time values.
Fig. 5 – Critical value for cost uncertainty and tax values. Fig. 7 – Expected time for cost uncertainty and critical values.
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dx.doi.org/%2010.1016/j.jval.2013.12.008. The simulations carried
out on critical values of cost shock conﬁrm results of comparative
statics discussed above. Figure 1 reveals that the trigger value is
much more sensitive to s than to α. This is because the higher the
cost uncertainty, the higher the risk of treatment switch, and
thus the higher the threshold to trigger the use of the second-line
treatment. Figure 2 illustrates that the dampening inﬂuence of
higher μ on the critical value strengthens as s increases.
Figure 3 shows that the trigger value rises when both φ
and π increase. It illustrates that as T2 becomes less cost com-
petitive, the uncertainty about using the second-line treatment
decision becomes more dominant. With limited substitutability,
higher quality of T2 will increase the demand for T2 disregarding
the cost uncertainty of treatment switch. The accentuated cur-
vature of the surface graphed in Figure 3, in which the critical
value rises very quickly as both φ is high and π is low, indicates
that the lower the cost-quality relationship, the more the uncer-
tainty of use of the second-line treatment decision becomes
dominant.
Figure 4 illustrates that as soon as one is expected to use the
new technology, the uncertainty about the use of the second-line
treatment decision becomes more dominant. Figure 5 illustratesFig. 6 – Expected probability for cost uncertainty and critical
values.the impact of s and τ on the critical value of treatment switch,
showing that the lower is the patient’s health capital, the higher
is the uncertainty regarding the treatment switch decision.
Figures 6 and 7 illustrate, respectively, the impact of s and x
on the expected probability of treatment switch and on the
probability of optimal treatment switch, as given by Equations 9
and 10.
In Figure 6, when α > (s2/2), the probability that ~x will be hit in
the future is increasing in x and decreasing in s2. This is because,
ﬁrst, the lower is s2, the less valuable is the option to switch
treatment, and so the more treatment switches will be observed,
and second, the higher is x, the more likely it is that the process
will be “thrown off-course” by a sequence of positive shocks
toward the optimality threshold.
In Figure 7, our simulation benchmark values are expressed in
year terms, so that simulations for the expected time for optimal
treatment switch can be read in years. Figure 7 shows that the
lower is s2 and the higher is x, the sooner the treatment switch is
expected to occur. The further away x is from the trigger value,
however, the greater is the effect of an increase in s2 on the delay
expected before treatment switch becomes optimal.
In summary, the lower the volatility of cost, the more likely
treatment switch is to become optimal and the sooner it is
expected to occur. Moreover, treatment switch becomes likelier
and is expected sooner, the closer is the system to the critical
threshold, that is, the closer x is to ~x.
Empirical results suggest that the existence of an option value
means that the ﬁrst-line treatment may be the better choice
when considering lifetime welfare. Thus, under irreversibility,
low-risk patients must begin the second-line treatment as soon
as possible, which is precisely when the second-line treatment is
least valuable.Conclusions
Our stochastic dynamic model of sequential therapeutic regimes
underlines the importance to characterize uncertainty. Growth in
the availability of treatments for chronic diseases that require
permanent intervention, along with general increases in life
expectancy, suggests that the effect of omitting option values
from evaluations will only become larger. In this article, we
addressed these intertemporal dependencies by explicitly model-
ing the cost uncertainty.
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ingly important for patients who might switch treatments. This
article sets up a stochastic model that provides an optimal rule
for the timing of treatment switch. In the real world, cost
ﬂuctuations among other factors render the outcome of any
treatment switch uncertain, so that decision makers might have
to wait for more information before optimally switching treat-
ments, especially when the incremental cost per QALY gained
cannot be fully recovered later on. Because in most cases decision
makers are not compelled to switch treatments at any speciﬁc
moment, they hold an option to switch treatments that should be
exercised only when it is optimal to do so.
Viewed from the perspective of real option theory, this article
sheds new light on some debates about switching treatments. Our
theoretical model suggests that cost uncertainty reduces the
expected NB. In addition, cost volatility discourages switching
treatments. The stochastic model also illustrates that as technolo-
gies become less cost competitive, the cost uncertainty becomes
more dominant. With limited substitutability, higher quality of
technologies will increase the demand for these technologies
disregarding the cost uncertainty. Several key insights emerge.
Irreversibility raises the value of the option-preserving treatment.
The existence of an option value means that a seemingly poorer
treatment may be the better choice when considering lifetime
welfare. Optimal decision making requires a careful comparison
of the “costs” of a less effective treatment for a condition today with
the “beneﬁts” of more effective treatments in the future.
The intuition for these results is deepened when we recognize
that one of the principal features driving our results is that
patients have particular characteristics that make technology’s
cost uncertain. Thus, under irreversibility, low-risk patients must
begin the option-preserving treatment as soon as possible, which
is precisely when the second-line treatment is least valuable. As
the costs of reversing current treatment impacts fall, it becomes
more feasible to provide the option-preserving treatment to these
low-risk individuals later on.
These results are critical given the expiration of the patent for
imatinib in 2015 for the United States and in 2016 for the
European Union. Because imatinib offers the most effective
response rate and durability for the initial treatment of GIST,
the ability for society to obtain less costly generic imatinib may
substantially change the enthusiasm for consumers and insur-
ance payers alike to consider alternative treatments as a viable
treatment option unless undoubted clinical beneﬁt can be estab-
lished. This dynamic interplay between drug manufacturers,
insurance providers, hospitals, and policymakers will continue
to unfold over the next several years.
There are limitations to this model that temper the applica-
tion of its conclusions to health care decision making. This model
considered the two most commonly used drug regimens in GIST
and did not include more recently studied medications, such as
regorafenib [30], or cytoreductive surgery [31]. These drugs may
change survival probabilities and costs because they are more
costly than BSC when second- and third-line treatments fail.
Our basic framework of option valuation highlights poten-
tially important macro-level strategies to improve social welfare
through medical technologies. Research investments that focus
on transforming irreversibility from complete to partial could
generate large social beneﬁts. Investments in the development of
alternative treatments for future diseases are also important, but
the return to such investments will depend on the degree of
irreversibility.
The greatest obstacle to translating theory to practice is the
intensive data requirement, which in some cases would require
coordination across ﬁrms whose products might interact.
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